College of Pharmaceutical Sciences, Xinjiang Medical University, Urumqi, 830011, China.
Xinjiang Uygur Autonomous Region Institute for Drug Control, Urumqi, 830054, China.
BMC Complement Med Ther. 2021 Apr 22;21(1):127. doi: 10.1186/s12906-021-03303-4.
Probiotics may have beneficial effects on patients with type 2 diabetes mellitus (T2DM). We separated 4 lactobacillus and 1 saccharomycetes from traditional fermented cheese whey (TFCW) and prepared composite probiotics from camel milk (CPCM) and investigated their effects on glucose and lipid metabolism, liver and renal function and gut microbiota in db/db mice.
CPCM was prepared in the laboratory and 40 db/db mice were randomly divided into 4 groups as metformin, low-dose and high-dose group and model group, and treated for 6 weeks. In addition, 10 C57BL/Ks mice as normal control group were used for comparison. Fasting blood glucose (FBG), body weight (BW), oral glucose tolerance test (OGTT), glycated hemoglobin (HbAlc), C-peptide (CP), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), 24 h urinary microalbumin (24 h malb), urine ketone, urine sugar, pancreas and liver tissue and intestinal flora were tested.
Compared to diabetic group, high dose CPCM significantly decreased FBG, OGTT, HbAlc and IRI, plasma TC, TG, LDL-C, 24 h malb, urine ketone and urine sugar, increased CP, HDL-C levels, improved the liver and kidney function, protected the function of islets, also increased intestinal tract lactic acid bacteria and Bifidobacterium, decreased Escherichia in db/db mice.
CPCM decreased FBG, OGTT and HbAlc, increased CP, modulated lipid metabolism and improved liver and kidney protected injury in db/db mice, which may be related to various probiotics acting through protecting the function of islets and regulating intestinal flora disturbance.
益生菌可能对 2 型糖尿病(T2DM)患者有有益影响。我们从传统发酵乳清奶酪(TFCW)中分离出 4 种乳酸菌和 1 种酵母菌,并从骆驼奶(CPCM)中制备复合益生菌,研究其对 db/db 小鼠葡萄糖和脂质代谢、肝肾功能和肠道微生物群的影响。
在实验室中制备 CPCM,将 40 只 db/db 小鼠随机分为 4 组,即二甲双胍组、低剂量组和高剂量组及模型组,治疗 6 周。此外,还使用 10 只 C57BL/Ks 小鼠作为正常对照组进行比较。检测空腹血糖(FBG)、体重(BW)、口服葡萄糖耐量试验(OGTT)、糖化血红蛋白(HbAlc)、C 肽(CP)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、24 小时尿微量白蛋白(24 h malb)、尿酮体、尿糖、胰腺和肝脏组织及肠道菌群。
与糖尿病组相比,高剂量 CPCM 能显著降低 FBG、OGTT、HbAlc 和 IRI,降低 TC、TG、LDL-C、24 h malb、尿酮体和尿糖,增加 CP、HDL-C 水平,改善肝肾功能,保护胰岛功能,增加肠道乳酸杆菌和双歧杆菌,减少 db/db 小鼠肠道内大肠杆菌。
CPCM 降低 FBG、OGTT 和 HbAlc,增加 CP,调节脂质代谢,改善 db/db 小鼠肝肾功能损伤,这可能与多种益生菌通过保护胰岛功能和调节肠道菌群紊乱有关。